NIAID’s point of contact for this service is Mr. Lester Freeman.
Requesting Access to NIAID Contract Services
This service provides evaluation of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as a microbicide. NIAID does NOT offer the primary screening of previously untested products via this service. Products must be single-component entities of known chemical structure; evaluation of multi-component natural product extracts is not supported.
Products are evaluated for topical microbicide potential using the following screening algorithm (published in Antimicrobial Agents and Chemotherapy. 2008 May; 52(5): 1768–1781).
Decision Point: If Therapeutic Index (TI= TC50/IC50, where TC50 = 50% inhibitory concentration in cytotoxicity assay and IC50 = 50% inhibitory concentration in anti-HIV assay) for Primary Assay 1 is ≥10 for colorless products or ≥50 for colored products, Confirmatory Assays will be initiated. If TIs fail to meet these cutoffs, further evaluation of the product is terminated.
Decision Point: If TIs remain ≥10 for colorless products or ≥50 for colored products, Secondary Assays will be initiated. If TIs fail to meet these cutoffs, further evaluation of the product is terminated.
Decision Point: The most highly ranked compounds from Secondary Assays are evaluated in Specialized Assays.
The current contractor for this service is Southern Research Institute, Frederick, MD.
Last Updated July 07, 2009